This content is generated by AI. You can give feedback on it in the Inderes forum.
In connection with Rovsing's Q3 report and rights issue announcement for the financial year 2025/26, we have updated our investment case one-pager.
Q3 showed a sequential improvement following a challenging first half, with revenue of DKK 9.2 million versus DKK 7.5 million in Q3 2024/25 and EBITDA near breakeven versus DKK -0.4 million a year earlier. Nonetheless, the company expects to land at the low end of its revised full-year guidance, implying revenue of approximately DKK 33 million and EBITDA at the lower bound of the DKK -2.5 to 0.5 million range. The order backlog has declined to DKK 25.9 million from DKK 33.1 million at the end of H1 — reflecting deliveries progressing — but the more significant forward-looking signal is the DKK 140 million in submitted binding proposals on upcoming European flagship missions, which highlights the step-change in tender activity as the new ESA budget cycle gets underway.
The rights issue, with gross proceeds of DKK 10.4 million at a subscription price of DKK 30 per share, is fully guaranteed and carries no financing risk. Proceeds are earmarked for debt reduction and to fund growth initiatives under the Buy & Build strategy.
The investment case rests on two interconnected catalysts. First, the conversion of the DKK 140 million tender pipeline into order intake as ESA and European national programmes begin awarding contracts under the new budget cycle, a cycle approximately 30% larger than the previous one. With a build-to-book ratio of around 1, an orderbook that approaches the prior cycle peak of DKK 65 million would meaningfully change the financial profile. Second, the Buy & Build strategy offers a path to accelerated growth and improved investor visibility, as demonstrated by peers such as Scandinavian Astor Group. The rights issue provides the capital foundation to pursue both.
The key risks remain consistent with our prior analysis: project delays outside the company's control, execution risk on the Buy & Build strategy, uncertainty around U.S. space policy under the new administration, and near-term share price volatility related to the rights issue process. The CEO transition adds a layer of uncertainty, though the fully guaranteed financing removes one overhang.
On valuation, Rovsing trades at EV/Sales of 1.2x for 2025/26E versus a peer median above 3x — a discount that reflects the current earnings pressure, but which could narrow materially if order intake accelerates in line with the tender pipeline.
For more details on the current results and the rationale behind the rights issue watch our event with the management.
Disclaimer: HC Andersen Capital receives payment from Rovsing for a Digital IR subscription agreement. HC Andersen Capital is furthermore acting as financial and legal advisor to the company in connection with an ongoing capital raise and receives payment from the company in this regard. Michael Friis, 07:30, 08/05/2026.